EP2010651B1 - Gène mt-pfka tronqué mutant permettant la synthèse d'un fragment actif plus court de 6-phosphofructo-1-kinase - Google Patents

Gène mt-pfka tronqué mutant permettant la synthèse d'un fragment actif plus court de 6-phosphofructo-1-kinase Download PDF

Info

Publication number
EP2010651B1
EP2010651B1 EP07709552.9A EP07709552A EP2010651B1 EP 2010651 B1 EP2010651 B1 EP 2010651B1 EP 07709552 A EP07709552 A EP 07709552A EP 2010651 B1 EP2010651 B1 EP 2010651B1
Authority
EP
European Patent Office
Prior art keywords
gene
pfk
pfk1
fragment
aspergillus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Not-in-force
Application number
EP07709552.9A
Other languages
German (de)
English (en)
Other versions
EP2010651A2 (fr
Inventor
Matic Legisa
Mojca Bencina
Gregor Tevz
Maja Capuder
Tina Mlakar
Darija Oven
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kemijski Institut
Original Assignee
Kemijski Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kemijski Institut filed Critical Kemijski Institut
Publication of EP2010651A2 publication Critical patent/EP2010651A2/fr
Application granted granted Critical
Publication of EP2010651B1 publication Critical patent/EP2010651B1/fr
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01011—6-Phosphofructokinase (2.7.1.11)

Definitions

  • the subject of the invention is mutated truncated mt- pfk A gene encoding the synthesis of an active shorter fragment of 6-phosphofiucto-1-kinase (PFK1) as defined in the appended claims, with no posttranslational modification needed to induce the activity.
  • the subject of the invention is the use of mutated truncated gene and its protein product as defined in the appended claims for enhancing the rate of cell biomass synthesis and excretion of extracellular enzymes, as well as increasing the productivity of primary and secondary metabolites.
  • the invention is in the field of microbial biotechnology and biochemistry.
  • TCA tricarboxylic cycle
  • PFK1 6-phosphofructo-1-kinase
  • the enzyme is regulated by the feed back mechanism, by citrate and ATP inhibition. In other words its activity decreases when citric acid level, as an important intermediate of TCA cycle and ATP, as the final product of oxidative phosphorylation, increase over a certain level (Voet and Voet, 1995).
  • negative regulation of the enzyme activity diminishes the effectiveness of anapletoric reactions and consequently reduces the rate of synthesis of the final products.
  • a significant increase in the rate of product formation could be achieved by having undisturbed metabolic flow through glycolysis, which could be done by inserting a modified gene encoding PFK1 enzyme that would be resistant to citrate inhibition but sensitive to activation with specific effectors.
  • Aspergillus niger cells were subjected to mutations in order to make the enzyme resistant to citrate inhibition.
  • a mutant was isolated that showed reduced inhibition by citrate, however the enzyme retained only 20% of its maximal velocity when inhibitor was present at slightly increased concentration of 10 mM.
  • a partially increased resistance toward the citrate inhibition had no positive effect on elevating the rate of product formation (Schreferl et al., 1986).
  • reduced inhibition by citrate of PFK1 was obtained by cleaving 8 amino acid residues from the C-terminal part of the enzyme, isolated from the rabbit muscle. Modified enzyme has lost its activity only when 10 mM of citrate was present in the system, while the original enzyme was completely inactivated at 2.5 mM of inhibitor (Valaitis et al., 1987).
  • PFK1 isolated from Aspergillus niger cells showed more resistance toward the citrate inhibition in comparison to the enzymes from other organisms, yet 10mM of citrate almost prevented its catalytic activity.
  • Physiological concentration of citric acid in normal cells is in mM values, however in A. niger cells the citrate concentration can reach up to 10 mM (Legi a and Kidri , 1989).
  • PFK1 enzyme isolated from the fungus Aspergillus niger was in past often a subject of investigation (Habison et al., 1979; Habison et al., 1983; Schreferel et al.
  • the shorter PFK1 fragment was prepared from a truncated pfk A gene. A number of genes shortened at 3' end of the leading strain were prepared and transferred into A. niger cells. After induced phosphorylation, PFK1 activity characteristic for the shorter fragment was detected in homogenate of transformants carrying t- pfk A gene of specific length (Capuder, 2004). Intracellular phosphorylation was induced by the addition of sodium azide, a well known inhibitor of electron transport at cytochrome oxidase aa 3 site, which interrupts the synthesis of ATP which decreases the activity of trans-membrane proton pumps (H + -ATPases).
  • the enzyme is initially inactive. It is activated only after the phosphorylation of the protein molecule by cAMP-dependent protein kinase that is induced by an increase of cAMP level in the cells.
  • cyclic AMP is synthesised after specific changes that spontaneously appear in the medium or it might be triggered artificially by adding specific inhibitors, like azide, to the medium. According to our knowledge spontaneous drop of intracellular pH occurs only in one strain of A. niger (A60), where the shorter fragment could be spontaneously activated as well. In another A.
  • the aim of the invention is to solve the problem by the procedure that eliminates the need for phosphorylation of the protein molecule for its activation and enables in vivo synthesis of an active protein by inserting modified mt- pfk A gene.
  • De-regulated glycolytic flux is of up-most importance in commercial micro-organisms for achieving high rates of specific productivity. Such conditions can be accomplished by inserting mutated, truncated mt- pfk A gene, encoding active shorter fragment of PFK1 enzyme that is resistant to citrate inhibition, while other effectors increase its activity to a greater extend in respect to the native enzyme.
  • the present invention relates to the following embodiments which are defined in items 1 to 16.
  • the present invention addresses the mutated gene, encoding active shorter fragment of 6-phosphofructo-1-kinase, as defined in the appended claims where phosphorylation of the protein molecule is not needed for its activation, whose monomeric molecular mass is between 30 and 55 kDa; whose enzyme activity is not significantly inhibited by citric acid or citrate salts or ATP.
  • the present invention concentrates on the mutated gene encoding shorter fragment of PFK1 as defined in the appended claims that is active immediately after its synthesis and is not inhibited by citric acid, or citrate salts in the range from 0 mM to 10 mM or ATP up to 1,5 ATP in the presence of fructose-2,6-bisphosphate.
  • the invention addresses the modified gene encoding the synthesis of active shorter fragment of PFK1 that can be activated by some metabolites such as fructose-2,6-bisphosphate, ammonium ions and AMP.
  • the shorter fragment originates from the native enzyme with removed N- and/or C-terminal.
  • the present invention is based on observation that mutated truncated gene, encoding the active fragment of 6-phosphofructo-1-kinase as defined in the appended claims that is resistant to the inhibition by citric acid and/or citrate salts and ATP, increases the rate of primary and secondary metabolite synthesis in the cells.
  • the invention concentrates on a procedure that includes the use of the mutated gene as defined in the appended claims for the synthesis of the active shorter PFK1 fragment, or insertion of homologous or heterologous gene into the cells for increasing the rate of primary and secondary metabolite synthesis due to increased glycolytic flux.
  • PFK1 stands for the enzyme 6-phosphofructo-1-kinase (EC 2.7.1.11).
  • Term “shorter fragment” stands for the protein which number of amino acid residues is smaller than that of the native protein.
  • Term "shorter PFK1 fragment” stands for the PFK1 protein which number of amino acid residues is smaller than that of the native 6-phosphofructo-1-kinase that is normally present in genetically unmodified cells.
  • pfk A stands for the gene encoding 6-phosphofructo-1-kinase.
  • t- pfk A stands for truncated pfk A gene, which number of nucleotides is lower than that of the native pfk A gene, encoding the synthesis of shorter PFK1 fragment, which number of amino acid residues is lower than that of the native PFK1 enzyme.
  • Term “mutation” stands for permanent change in nucleotide sequence of a specific gene.
  • mutant pfk A gene stands for a permanent change of one or more nucleotides anywhere in the sequence of pfk A gene encoding PFK1 enzyme with change of one or more amino acid residues anywhere in the protein.
  • mutant mt- pfk A gene stands for permanent change of one or more nucleotides anywhere in the sequence of truncated t- pfk A gene encoding shorter PFK1 fragment with change of one or more amino acid residues anywhere in the protein.
  • 6-phosphofructo-1-kinase stands for the enzyme, that converts fructose-6-phosphate to fructose-1,6-bisphosphate on expense of ATP in the presence of Mg 2+ ions and is an enzyme in the process of glycolysis.
  • Term “inhibition by citric acid” stands for negative action of citric acid or its salts, such as citrates, on the enzyme activity of 6-phosphofructo-1-kinase.
  • Term “inhibition by ATP” stands for negative action of ATP on the enzyme activity of 6-phosphofructo-1-kinase.
  • activation stands for increasing the activity of the enzyme above the basic level in the presence of activating components such as: cellular metabolites, for instance fructose-2,6-bisphosphate and ammonium ions and AMP.
  • N- and/or C- terminal part of the protein stands for the part of the protein from the NH 2 - group or beginning of the protein toward the central part of the protein and from the central part of the protein toward the COOH- group or the terminal part of the protein.
  • post-translational modification stands for a change in amino acid sequence of the protein by cleaving the protein by proteases or by attaching other bio-chemically functional groups to amino acid sequence, such as the addition of phosphate group by a process of phosphorylation catalysed by protein kinase. Post-translational modifications are described in the scientific literature.
  • Term “metabolites” stands for the products of cellular metabolism.
  • Term “originating or the native enzyme or the gene” stands for the enzyme of 6-phosphofructo-1-kinase and the gene encoding the enzyme, that is present in the cells.
  • Term “recombinant origin” stands for the gene or protein that is modified by the laboratory techniques known to the experts form the field.
  • Synthetic origin stands for the synthetically made gene or protein that is prepared by the techniques known to the experts form the field. Synthetic protein could be represented by the combination of animal and microbial protein.
  • Term “restriction at 5' and/or 3' part of the native gene” stands for the removal of the gene from 5' part toward the central part and/or removal from the central part toward the 3' part of the gene. Removal is conducted by techniques known to the experts from the field and can be done by specific endonucleases, un-specific cleavage or by multiplying the gene by the method of Polymerase Chain Reaction by the use of oligo-nucleotide primers, that are complementary to the gene at 5' and 3' end.
  • mutated homologous recombinant gene stands for the mutated gene encoding shorter fragment, prepared by the recombinant techniques and is introduced into the cells of the same species as the native gene comes from.
  • mutated recombinant gene stands for the mutated gene encoding shorter fragment, prepared by the recombinant techniques and is introduced into the cells of other species as the native gene comes from.
  • the invention deals with the gene encoding the shorter, genetically modified fragment of 6-phosphofructo-1-kinas as defined in the appended claims that is active immediately after the synthesis, therefore no phosphoryltion of protein molecule is needed for its activation; and in the presence of citric acid and/or citric acid salts up to concentration of 15 mM and ATP up to concentration 1,5 mM its activity is reduced for less than 30%; and can be activated by fructose-2,6-bisphosphate, ammonium ions and AMP; and is encoding a protein that differs for at least one amino acid residue of the original amino acid sequence of shorter fragments and which genes are present in the genomes of microbial, animal or plant origin, preferably fungi, preferably from the species Aspergillus, Trichoderma, Penicillium, Pichia, Saccharomyces, Schizosaccharomyces, Candida, Kluyveromyces, Neurospora, preferably Aspergillus niger.
  • the gene encodes a shorter, genetically modified fragment of PFK1 with molecular mass higher than 30 kDa and lower than 55 kDa, which has no N- and/or C- terminal part of the native 6-phosphofructo-1-kinase.
  • the invention concentrates on the gene encoding the shorter, genetically modified fragment of PFK1 as defined in the appended claims that is active immediately after the synthesis, therefore no phosphorylation of protein molecule is needed for its activation; and in the presence of citric acid and/or citric acid salts up to concentration of 15 mM and ATP up to concentration 1,5 mM its activity is reduced for less than 30%; and can be activated by fructose-2,6-bisphosphate, ammonium ions and AMP; and is encoding a protein with amino acid residue sequence SEQ ID NO:1 or SEQ ID NO:2, that differs for at least one amino acid residue from amino acid sequence of the shorter PFK1 fragment of the sequence SEQ ID NO:3, which gene sequence SEQ ID NO:4 is present in the genome of Aspergillus niger ; and encodes a protein with molecular mass higher than 30 kDa and lower than 55 kDa, which has no N- and/or C- terminal part of the native 6-phosphofructo
  • the invention deals with an expression vector as defined in the appended claims that carries the above mentioned gene functionally connected to controlling sequences, promoter, and other relevant, DNA sequences enabling protein synthesis, which is coded by the gene and expression vector that enables expression of the gene in eukaryotic host cells or prokaryotic host cells, preferably animal tissue cultures, plant tissue cultures, filamentous fungi, yeasts, bacteria, preferably filamentous fungi, preferably from the genus Aspergillus, Trichoderma, Penicillium, and preferably yeasts, preferably from the genus Pichia, Saccharomyces, Schizosaccharomyces, and preferably bacteria, preferably from the genus Acetobacter, Escherichia, Bacillus, Streptomyces, Zymomonas, preferably in filamentous fungi of the genus Aspergillus, preferably Aspergillus niger, Aspergillus terreus, Aspergillus oryzae.
  • the inventions deals with the organisms as defined in the appended claims that contain above mentioned gene and/or above mentioned expression vector and that the above mentioned expression vector that corresponds to a specific organism, is inserted into above mentioned organism by the laboratory techniques known to the experts form the field in a way that enables expression of the above mentioned gene and the organisms are of microbial origin, preferably filamentous fungi, preferably from the genus Aspergillus, Trichoderma, Penicillium, and yeasts preferably from the gene Pichia, Saccharomyces, Schizosaccharomyces, or filamentous fungi from the genus Aspergillus, preferably Aspergillus niger, Aspergillus terreus, Aspergillus oryzae, or bacteria preferably from the genus Acetobacter, Escherichia, Bacillus, Streptomyces, Zymomonas and of plant and animal origin, preferably tissue cultures of plant and animal origin.
  • microbial origin preferably filamentous fungi
  • the invention concentrates on the use of the above mentioned gene and/or expression vectors and/or the above mentioned organisms as defined in the appended claims for the rise of metabolic flux through glycolysis to enhance anaplerotic reaction during the process of bioproducts formation, preferably cell biomass; homologous and heterologous proteins; primary metabolites, such as ethanol, acetate, lactate, organic acids, amino acids, polyols; secondary metabolites, such as antibiotics, ergot alkaloids, statins, vitamins, immuno-modulators, citostatics, insecticides, herbicides.
  • primary metabolites such as ethanol, acetate, lactate, organic acids, amino acids, polyols
  • secondary metabolites such as antibiotics, ergot alkaloids, statins, vitamins, immuno-modulators, citostatics, insecticides, herbicides.
  • the invention concentrates on the process for bio-products formation as defined in the appended claims that include the use of the above mentioned gene that is inserted in the above mentioned expression vectors that is introduced into the above mentioned organisms and that the above mentioned organism is cultivated in a way to synthesise the bio-product.
  • Plasmid pGWII that was used for silencing of pryG gene, was prepared from pGW635 plasmid (Goosen et al., 1987) carrying pyr G gene of A. niger and pBluescript II KS+ (Stratagene, La Jolla, CA).
  • Expression vector pMOJ004 originates from pBluescript II KS+ plasmid (Stratagene, La Jolla, CA) with integrated promoter region of gene encoding for gliceraldehyde-3-phosphate dehydrogenase ( gpd A) and termination region of the gene encoding for glutamine amido transferase ( trp C) of the fungus Aspergillus nidulans.
  • gpd A gliceraldehyde-3-phosphate dehydrogenase
  • trp C glutamine amido transferase
  • Promoter gpd A was amplified by the PCR method by using pAN7-1 vector (Z32698) as a template and gpd A specific oligonucleotide primers: 5'-GAGCTCGTGACCGGTGACTCTTTC-3'(SEQ ID No: 5) and 5'-TCTAGATGCATATGGGTGATGTCTGCTCAAGC-3' (SEQ ID No: 6), that simultaneously enabled the insertion of Sst I and Xba I -Nde I restriction sites at the 5' end.
  • trp C terminator region (X023390) was amplified by using the following oligonucleotide primers: 5'-CCATGGGTCTAGACGGATCCTAGTGATTTAATAGCTCCATGTC-3' (SEQ ID No: 7) and 5'-GAATTCAAGCTTCCGCGGCCGGGTATTGGGTG-3' (SEQ ID No: 8) that simultaneously enabled the insertion of Xba I/ Bam HI and Xho I restriction sites at the 5' end.
  • Sst I and Xba I enzymes While for trp C terminator region the restriction was made by Xba I and Xho I enzyme.
  • Nde I/ Apa I-ATT -Bam HI fragments of A. niger pfk A gene (EMBL Accession No. pfk A Z79690) was amplified by PCR reaction by using following primers: : 5'-CCG CGG ATG CAT ATG GCT CCC CCC CAA GC-3' (SEQ ID No: 9) and 5'-TGG ATC CTT ACC CGG GAT CAT AGT GCC GGC ACA GAC C-3' (SEQ ID No: 10) and subcloned into Eco RV digest of pBluescript II KS+ (pBS)(Stratagene, La Jolla, CA).
  • Mutagenesis was conducted by QuikChange II XL Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) by using the following oligonucleotide primers: for changing T89E, 5' -CC GCC CGC TGC ATG GAG TTC CGT GAG CGC CC-3' (SEQ ID No: 11) and 5'-GG GCG CTC ACG GAA CTC CAT GCA GCG GGC GG-3' (SEQ ID No: 12); for changing G95I, 5'-C CGC TGC ATG GAG TTC CGT GAG CGC CCC ATC CGT CTG CGG G-3' (SEQ ID No: 13) and 5'-C CCG CAG ACG GAT GGG GCG CTC ACG GAA CTC CAT GCA GCG G-3' (SEQ ID No: 14).
  • Mutated t- pfk A gene was designated as mt- pfk A gene.
  • niger Site at N-terminal part Changed amino acid residue in a protein encoded by Mt- pfk A gene Cysteine 87 Phenilalanine Methionine 88 Proline Glutaminic acid 92 Aspartic acid Arginine 93 Glutamic acid Proline 94 Asparagine
  • Mt- pfk A gene was ligated into the pALTER-Ex1 plasmid under the control of tac promoter. After cloning the sequence of Mt- pfk A gene inserted into the pALTER-Ex1 vector was checked (MWG-Biotech, Edberg, Germany).
  • Mycelium of A . niger was harvested after 16-18 hours of submerged growth in a complex medium. Protoplast formation and transformation was conducted as reported previously (Kusters-van Someren et al., 1991), only that lytic enzyme Caylase-4 (Cayla, Toulouse, France) was used instead of Novozyme 234. As a selection marker pyr A gene located on pGW635 plasmid was used.
  • Chromosomal DNA (3 ⁇ g) of transformants was degraded overnight by 30U of Bam HI restriction enzyme in a final volume of 200 ⁇ l. DNA molecules were separated on 0,5% agarose gel (1xTris-acetate-EDTA buffer with 2 ⁇ l/ml of etidium bromide) and bloted on nylon membrane (Hybond TM -N + , Amersham). Single stranded DNA was cross-linked to membrane by UV light (Biometra Ti3, Biometra, Goetingen, Germany). DNA probe was prepared from Nde I/ Bam HI cut of the pRCR- pfk A plasmid and labeled with BioPrime DNA Labeling System (Life Technologies) according to the instructions. Chemiluminescence detection with CDP-Star (Roche Applied Science) was done by exposure of membranes to X-Omat AR film (Kodak).
  • Mycelium of A . terreus was harvested after 16-18 hours of submerged growth in a complex medium. Protoplast formation and transformation was conducted as reported previously (Kusters-van Someren et al., 1991), only that lytic enzyme Caylase-4 (Cayla, Toulouse, France) was used instead of Novozyme 234.
  • A. terreus transformants with integrated mt- pfk A genes were isolated after protoplasts were co-transformed with pMOJ004-mt- pfk A plasmid and pUT720 plasmid, carrying gene for phleomycin resistance.
  • Plasmid pAlter-Ex1 carrying Mt- pfk A gene was inserted into E.coli strain DF 1010, with deleted bacterial pfk A and pfk B genes. Effectiveness of transformation was tested by growth of bacteria on selective medium. Plasmid pALTER-Ex1 contains a gene for expression of tetracycline resistance in bacterial cells.
  • Transformant with integrated t- pfk A gene were grown on minimal medium for 14 hours as described under 1.1.1.
  • Sodium azide was added to the medium in final concentration of 1mM and culture incubated for additional 15 minutes.
  • Azide a well known inhibitor of electron transport over cytochromes causes protons to accumulate in the cells, which results in a drop of intracellular pH.
  • Cells respond by the synthesis of a signalling molecule - cyclic AMP to the slight acidification.
  • CyclicAMP activates cAMP-dependent protein kinase that ultimately phosphorylates shorter fragment of PFK1 encoded by t- pfk A gene.
  • Different PFK1 kinetic parameters were detected in cell-free extracts of transformants after phosphorylation was induced, while no change in kinetics could be observed in parental strain in spite of induced phosphorylation.
  • Transformants with integrated mt- pfk A gene that enabled synthesis of modified shorter PFK1 fragment were grown for 14 hours on a minimal medium as described under 1.1.1. No sodium azide was added to the medium prior to measuring PFK1 kinetics in cell free extracts. The presence of active shorter fragment of PFK1 has been confirmed by detection of PFK1 kinetics characteristic for the shorter fragment.
  • Mycelium was collected by suction filtration and washed with cold 50 mM phosphate buffer containing 0,5mM dithioerithritol (DTE) and 1mM EDTA.
  • DTE dithioerithritol
  • PFK1 activity was measured spectrophotometrically at 340 nm according to slightly modified procedure of Legi a and Mattey, 1988, using a coupled reaction system.
  • the auxiliary enzymes remained active for several weeks when stored in refrigerator.
  • the measurements have started with adding fructose-6-phosphate and 0,1 mM ATP to the system, followed by increasing the concentration of ATP to 1mM and finally in the presence of 4 ⁇ M of fructose-2,6-bisphosphate.
  • Alpha-amylolytic activity was measured in the medium filtrate as described under the Example 2.2., by using commercial Kit for evaluation of ⁇ -amylolytic activity according to the Ceralpha method (Megazyme, Bray, Ireland).
  • the fungus was grown in a medium that contained the following ingredients in 1 litre: 150g sucrose, 2,5g (NH 4 ) 2 SO 4 , 1,5g KH 2 PO 4 , 0,5g MgSO 4 x7H 2 O, 6,5 mg FeSO 4 , 1,3 mg ZnSO 4 .7H 2 O with pH value adjusted to 2,5.
  • the amount of citric acid in the medium filtrate was determined as reported previously (Legi a and Jernejc, 2002). Data are means of five independent experiments inoculated with individual strain/transformant.
  • transformants of A60 strain with inserted t- pfk A gene showed increased citric acid production in respect to their parental strain ( Figure 3b ).
  • Less active H + -ATPases were described in A60 strain (Jernejc and Legi a, 2002) that cause a drop of intracellular pH value during the growth in citric acid yielding medium, which finally induces cAMP synthesis and phosphorylation of the shorter PFK1 fragment.
  • the medium of the following composition contained in 1 litre: 20g starch, 6,0g NaNO 3 , 1,5g KH 2 PO 4 , 0,5g MgSO 4 .7H 2 O, 0,5g KCl, 0,1g EDTA, 44 mg ZnSO 4 , 10mg MnCl 2 .4H 2 O, 3,2 mg CoCl 2 .6H 2 O, 3,2 mg CuSO 4 .5H 2 O, 2,2 mg (NH 4 ) 6 Mo 7 O 24 .4H 2 O, 14,7mg.CaCl 2 .2H 2 O, 10 mg FeSO 4 .7H 2 O, agar 1,5% (m/v).
  • Agar plates containing the medium were inoculated with 5 ⁇ l of spore suspension of both A. niger strain A158 and transformant An-TEGI23. After three days of incubation at 30°C the plates were poured with iodine solution (J 2 0,4M/KJ 0,4M) and the clearing zones measured around the colonies ( Figure 5 ).
  • Transformant with integrated mt- pfk A genes grew faster and the colony diameter reached 26mm, while the parental strain diameter was smaller - 22mm. After staining with the iodine solution a clearing zone could be observed around the colony of transformant, while no starch was degraded around the colony but only beneath the mycelium of the parental strain.
  • Alpha-amylolytic activity of the parental A. niger strain (A158) and transformant with integrated mt- pfk A genes (An-TEGI23) was detected during the submerged growth in the medium as described above, without agar added. The activity was determined in the filtrate of fermentation broths according to Ceralpha method. Data are means of three independent experiments and are shown in Figure 6 .
  • the strains of Aspergillus terreus were grown in productive medium as described previously (Riscaldati et al., 2000) and contained in 1 litre: 150g glucose, 2,36 g (NH 4 ) 2 SO 4 , 0,11g KH 2 PO 4 , 208 mg MgSO 4 x7H 2 O, 130 mg KCl, 74 mg NaCl, 0,2 mg CuSO 4 .5H 2 O, 5,5 mg FeSO 4 .7H 2 O, 0,7 mg MnCl 2 .4H 2 O, 1,3 mg ZnSO 4 .7H 2 O, pH adjusted to 3,4.
  • the amount of itaconic acid was determined by ionic chromatography by using CIM discs and itaconate as a standard. The data are means of five independent experiments inoculated with the same strain/transformant.
  • Figure 6 shows the amount of accumulated itaconate by parental strain and transformant At-TEGI-1. In transformant carrying higher number of integrated mt- pfk A genes, the yields of itaconic acid were increased up to 40%.
  • E . coli Parental strains and double transformants of the bacterium E . coli were grown on minimal medium in the presence of the following carbon-hydrates as sole carbon sources: glucose, fructose, mannose and manitol. IPTG was added to the medium that promoted constitutive expression of Mt- pfk A gene. Apart from E . coli strain carrying Mt- pjk A gene the following E . coli strains were tested. BL21 strain, DF 1020 strain, DF 1020 strain with integrated native pfk A gene of Aspergillus niger, DF 1020 strain with integrated t- pfk A gene. After the incubation at 37°C for several days, growth of individual colonies was observed. Growth rates of colonies have been evaluated and are shown in Table 6.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Claims (16)

  1. Gène codant pour un court fragment génétiquement modifié de la 6-phosphofructo-1-kinase, qui est actif immédiatement après synthèse, aucune phosphorylation de la molécule protéique n'étant donc nécessaire à son activation,
    a. qui perd moins de 30 % d'activité enzymatique en présence d'acide citrique et/ou de sels d'acide citrique à une concentration jusqu'à 15 mM et d'ATP à une concentration jusqu'à 1,5 mM,
    b. qui est activé par le fructose-2,6-bisphosphate, les ions ammonium et l'AMP, codant pour une protéine ayant une séquence d'acides aminés présentée dans SEQ ID NO:1 ou SEQ ID NO:2, qui diffère par au moins un résidu d'acide aminé de la séquence d'acides aminés du fragment de PFK1 plus court qui provient de la protéine native ayant la séquence SEQ ID NO:3, dont la séquence génique SEQ ID NO:4 est présente dans le génome du champignon Aspergillus niger.
  2. Gène codant pour un court fragment génétiquement modifié de PFK1 selon la revendication 1, dans lequel la masse moléculaire de la protéine codante est supérieure à 30 kDa et inférieure à 55 kDa.
  3. Vecteur d'expression portant un gène selon la revendication 1 ou 2 qui est fonctionnellement lié à des séquences régulatrices, des promoteurs ou d'autres séquences d'ADN pertinentes, permettant l'expression génique selon n'importe lesquelles des revendications 1 à 3.
  4. Vecteur d'expression selon la revendication 3 qui permet l'expression génique selon l'une quelconque des revendications 1 à 3 dans des cellules hôtes eucaryotes ou des cellules hôtes procaryotes.
  5. Vecteur d'expression selon la revendication 3 ou 4 qui permet l'expression génique selon la revendication 1 ou 2 dans des cellules hôtes eucaryotes, de préférence dans les champignons filamenteux et les levures.
  6. Vecteur d'expression selon l'une quelconque des revendications 3 à 5 qui permet l'expression génique selon la revendication 1 ou 2 dans les champignons filamenteux, appartenant de préférence aux genres Aspergillus, Trichoderma, Penicillium ; dans les levures, appartenant de préférence aux genres Pichia, Saccharomyces, et dans les bactéries appartenant aux genres Acetobacter, Escherichia, Bacillus, Streptomyces, Zymomonas.
  7. Vecteur d'expression selon l'une quelconque des revendications 3 à 5, qui permet l'expression génique selon la revendication 1 ou 2 dans les champignons filamenteux appartenant au genre Aspergillus, de préférence dans Aspergillus niger, Aspergillus terreus, Aspergillus oryzae.
  8. Organisme non humain comprenant un gène codant pour un fragment génétiquement modifié plus court de PFK1 selon la revendication 1 ou 2 et/ou un vecteur d'expression selon l'une quelconque des revendications 3 à 7, dans lequel le gène et/ou le vecteur d'expression qui correspond à un organisme spécifique est inséré dans un organisme spécifique à l'aide de techniques appropriées connues des experts du domaine, permettant l'expression du gène selon l'une quelconque des revendications 1 à 3.
  9. Organismes selon la revendication 8, lesquels organismes sont d'origine microbienne, animale ou végétale.
  10. Organismes selon la revendication 8 ou 9, lesquels organismes consistent en une culture de tissu d'origine animale ou végétale.
  11. Organismes selon la revendication 8 ou 9, lesquels organismes étant des champignons filamenteux, des levures ou des bactéries.
  12. Organismes selon la revendication 8 ou 9, lesquels organismes sont des champignons filamenteux, appartenant de préférence aux genres Aspergillus, Trichoderma, Penicillium ; des levures appartenant de préférence aux genres Pichia, Saccharomyces, Schizosaccharomyces et des bactéries appartenant aux genres Acetobacter, Escherichia, Bacillus, Streptomyces, Zymomonas.
  13. Organismes selon la revendication 8 ou 9, lesquels organismes sont des champignons filamenteux, appartenant de préférence au genre Aspergillus, de préférence Aspergillus niger, Aspergillus terreus, Aspergillus oryzae.
  14. Utilisation d'un gène codant pour un court fragment génétiquement modifié de PFK1 selon la revendication 1 ou 2 et/ou du vecteur d'expression selon l'une quelconque des revendications 3 à 7 et/ou de l'organisme selon l'une quelconque des revendications 8 à 13 pour augmenter le flux métabolique à travers la glycolyse afin de renforcer la réaction anaplérotique au cours des processus de formation de bio-produits.
  15. Utilisation selon la revendication 14, dans laquelle les bio-produits sont de préférence de la biomasse cellulaire ; des protéines homologues et hétérologues ; des métabolites primaires tels que l'éthanol, l'acétate, le lactate, des acides organiques, des acides aminés, des polyols ; des métabolites secondaires tels que : antibiotiques, alcaloïdes de l'ergot de seigle, statines, vitamines, immunomodulateurs, cytostatiques, insecticides, herbicides.
  16. Procédure pour la formation de bio-produits qui inclut l'utilisation du gène selon la revendication 1 ou 2, qui est inséré dans le vecteur d'expression selon l'une quelconque des revendications 3 à 7 et est transféré dans l'organisme selon l'une quelconque des revendications 8 à 13, ledit organisme étant cultivé d'une façon qui permet la synthèse de bio-produits.
EP07709552.9A 2006-04-26 2007-02-27 Gène mt-pfka tronqué mutant permettant la synthèse d'un fragment actif plus court de 6-phosphofructo-1-kinase Not-in-force EP2010651B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI200600107A SI22256A (sl) 2006-04-26 2006-04-26 MUTIRANI SKRAJĹ ANI GEN mt-pfkA ZA SINTEZO AKTIVNEGA KRAJĹ EGA FRAGMENTA 6-FOSFOFRUKTO-1-KINAZE
PCT/SI2007/000007 WO2007123498A2 (fr) 2006-04-26 2007-02-27 Gène mt-pfka tronqué mutant permettant la synthèse d'un fragment actif plus court de 6-phosphofructo-1-kinase

Publications (2)

Publication Number Publication Date
EP2010651A2 EP2010651A2 (fr) 2009-01-07
EP2010651B1 true EP2010651B1 (fr) 2013-05-08

Family

ID=38476863

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07709552.9A Not-in-force EP2010651B1 (fr) 2006-04-26 2007-02-27 Gène mt-pfka tronqué mutant permettant la synthèse d'un fragment actif plus court de 6-phosphofructo-1-kinase

Country Status (5)

Country Link
US (1) US7807404B2 (fr)
EP (1) EP2010651B1 (fr)
BR (1) BRPI0710863A2 (fr)
SI (1) SI22256A (fr)
WO (1) WO2007123498A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014142647A1 (fr) * 2013-03-14 2014-09-18 Wageningen Universiteit Souches fongiques ayant une production améliorée d'acide citrique et d'acide itaconique
SI24955A (sl) * 2015-03-25 2016-09-30 Kemijski Inĺ Titut Modificirana 6-fosfofrukto-1-kinaza, ki rekombinantnim celicam kvasovke Saccharomyces cerevisiae omogoča fermentativno uporabo pentoznih sladkorjev

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI21617A (sl) * 2003-09-09 2005-04-30 Kemijski inštitut Krajši fragment 6-fosfofrukto-1-kinaze

Also Published As

Publication number Publication date
US20090098605A1 (en) 2009-04-16
BRPI0710863A2 (pt) 2011-06-21
WO2007123498A3 (fr) 2007-12-21
WO2007123498A8 (fr) 2009-07-23
WO2007123498A2 (fr) 2007-11-01
EP2010651A2 (fr) 2009-01-07
SI22256A (sl) 2007-10-31
US7807404B2 (en) 2010-10-05

Similar Documents

Publication Publication Date Title
US8697416B2 (en) Recombinant polynucleotide, host cells containing the same and a process for producing a protein having aldolase activity
JP2021101708A (ja) Ｆｄｃａのデヒドロゲナーゼ触媒による生産
JP4248900B2 (ja) 新規なフルクトシルアミンオキシダーゼをコードする遺伝子及びそれを用いての該フルクトシルアミンオキシダーゼの製造方法
US20070141687A1 (en) Increase in stress tolerance with ascorbic acid during fermentation
KR20130101030A (ko) 변형된 미생물을 사용한 개선된 글리콜산 발효 생산
KR102149044B1 (ko) 2-히드록시 감마 부티로락톤 또는 2,4-디히드록시-부티레이트 의 제조 방법
Capuder et al. Highly active, citrate inhibition resistant form of Aspergillus niger 6-phosphofructo-1-kinase encoded by a modified pfkA gene
EP2010651B1 (fr) Gène mt-pfka tronqué mutant permettant la synthèse d'un fragment actif plus court de 6-phosphofructo-1-kinase
JP4815219B2 (ja) 好アルカリ性サイクロデキストラン合成酵素遺伝子を含有するｄｎａ、組み換え体ｄｎａ、および好アルカリ性サイクロデキストラン合成酵素の製造法
WO2002000898A1 (fr) Systeme de transformation de champignons appartenant au genre monascus
Kang et al. Cloning and characterization of a dextranase gene from Lipomyces starkeyi and its expression in Saccharomyces cerevisiae
KR101628856B1 (ko) 다기능성 베타-자일로시데이즈 b
CN115896211A (zh) 一种发酵生产胞磷胆碱的基因工程菌及应用
KR20210076915A (ko) 레바우디오사이드의 고효율 생산을 위한 스테비아 레바우디아나 카우레노산 수산화 효소 변이체
US7527953B2 (en) Genes from Propionibacterium freudenreichii encoding enzymes involved in vitamin B12 biosynthesis
ZUR et al. FRAGMENT OF 6-PHOSPHOFRUCTO-l-KINASE
Huang et al. Disruption of the peroxisomal citrate synthase CshA affects cell growth and multicellular development in Dictyostelium discoideum
JP4415247B2 (ja) 新規なグリセロールキナーゼ、該遺伝子及び該遺伝子を用いたグリセロールキナーゼの製造法
CN114517174B (zh) 合成三七素的工程菌和应用
TWI509072B (zh) 生產異丙醇的大腸菌及生產異丙醇的方法
KR102070415B1 (ko) 신규한 알파-아가레이즈 및 이를 이용한 한천 유래 홀수 개의 올리고당 생산 방법
EP1673442B1 (fr) Organismes transgeniques a basse temperature de croissance
KR20210120027A (ko) 레바우디오사이드의 고효율 생산을 위한 abc 수송체
WO2005023854A2 (fr) Fragment plus court de 6-phosphofructo-1-kinase
Yong et al. Cloning and Expression of a Chitinase Gene from Sanguibacter sp. C4

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081024

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20100215

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 611118

Country of ref document: AT

Kind code of ref document: T

Effective date: 20130515

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602007030311

Country of ref document: DE

Effective date: 20130704

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 611118

Country of ref document: AT

Kind code of ref document: T

Effective date: 20130508

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20130508

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130508

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130508

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130508

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130908

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130809

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130819

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130508

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130508

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130909

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130508

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130808

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130508

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130508

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130508

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130508

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130508

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130508

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130508

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130508

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130508

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130508

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20140211

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602007030311

Country of ref document: DE

Effective date: 20140211

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130508

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140227

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20140227

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140228

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140228

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20141031

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140227

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140227

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140228

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20150225

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130508

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20070227

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602007030311

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160901